FULGENT GENETICS, INC. Revenue
FULGENT GENETICS, INC. (FLGT) reported Revenue of $85.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-30
- FULGENT GENETICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $85.39M, a 4.38% increase year-over-year.
- FULGENT GENETICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $71.14M, a 3.16% decline year-over-year.
- FULGENT GENETICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $83.34M, a 9.34% increase year-over-year.
- FULGENT GENETICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $84.07M, a 17.18% increase year-over-year.
- FULGENT GENETICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $322.67M, a 13.83% increase from fiscal 2024.
- FULGENT GENETICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $283.47M, a 1.99% decline from fiscal 2023.
- FULGENT GENETICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $289.21M, a 53.27% decline from fiscal 2022.
- FULGENT GENETICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $618.97M, a 37.64% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $85.39M 10-Q · filed 2026-07-30 | $156.53M 10-Q · filed 2026-07-30 | $239.86M derived: sum of 3 quarters · filed 2026-07-30 | $323.93M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $71.14M 10-Q · filed 2026-05-01 | $154.47M derived: sum of 2 quarters · filed 2026-05-01 | $238.54M derived: sum of 3 quarters · filed 2026-05-01 | $320.35M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $83.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $167.41M derived: sum of 2 quarters · filed 2026-02-27 | $249.21M derived: sum of 3 quarters · filed 2026-07-30 | $322.67M 10-K · filed 2026-02-27 |
| 2025-09-30 | $84.07M 10-Q · filed 2025-11-07 | $165.87M derived: sum of 2 quarters · filed 2026-07-30 | $239.34M 10-Q · filed 2025-11-07 | $315.55M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $81.80M 10-Q · filed 2026-07-30 | $155.27M 10-Q · filed 2026-07-30 | $231.48M derived: sum of 3 quarters · filed 2026-07-30 | $303.22M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $73.46M 10-Q · filed 2026-05-01 | $149.68M derived: sum of 2 quarters · filed 2026-05-01 | $221.42M derived: sum of 3 quarters · filed 2026-05-01 | $292.45M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $76.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $147.96M derived: sum of 2 quarters · filed 2026-02-27 | $218.99M derived: sum of 3 quarters · filed 2026-02-27 | $283.47M 10-K · filed 2026-02-27 |
| 2024-09-30 | $71.74M 10-Q · filed 2025-11-07 | $142.77M derived: sum of 2 quarters · filed 2025-11-07 | $207.26M 10-Q · filed 2025-11-07 | $277.76M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $71.03M 10-Q · filed 2025-08-01 | $135.51M 10-Q · filed 2025-08-01 | $206.02M derived: sum of 3 quarters · filed 2026-02-27 | $290.70M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $64.48M 10-Q · filed 2025-05-02 | $134.99M derived: sum of 2 quarters · filed 2026-02-27 | $219.68M derived: sum of 3 quarters · filed 2026-02-27 | $287.53M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $70.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $155.19M derived: sum of 2 quarters · filed 2026-02-27 | $223.04M derived: sum of 3 quarters · filed 2026-02-27 | $289.21M 10-K · filed 2026-02-27 |
| 2023-09-30 | $84.69M 10-Q · filed 2024-11-08 | $152.54M derived: sum of 2 quarters · filed 2024-11-08 | $218.71M 10-Q · filed 2024-11-08 | $286.41M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $67.85M 10-Q · filed 2024-08-02 | $134.02M 10-Q · filed 2024-08-02 | $201.72M derived: sum of 3 quarters · filed 2024-08-02 | $307.38M derived: sum of 4 quarters · filed 2024-08-02 |
| 2023-03-31 | $66.17M 10-Q · filed 2024-05-03 | $133.87M derived: sum of 2 quarters · filed 2024-05-03 | $239.53M derived: sum of 3 quarters · filed 2024-05-03 | $364.87M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $67.70M 10-K · filed 2023-02-28 | $173.36M derived: sum of 2 quarters · filed 2023-11-03 | $298.70M derived: sum of 3 quarters · filed 2023-11-03 | $618.97M 10-K · filed 2025-02-28 |
| 2022-09-30 | $105.66M 10-Q · filed 2023-11-03 | $231.00M derived: sum of 2 quarters · filed 2023-11-03 | $551.26M 10-Q · filed 2023-11-03 | $802.93M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $125.34M 10-Q · filed 2023-08-04 | $445.61M 10-Q · filed 2023-08-04 | $697.28M derived: sum of 3 quarters · filed 2023-08-04 | $925.15M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $320.27M 10-Q · filed 2023-05-05 | $571.94M derived: sum of 2 quarters · filed 2023-05-05 | $799.81M derived: sum of 3 quarters · filed 2023-05-05 | $953.42M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $251.67M 10-K · filed 2023-02-28 | $479.54M derived: sum of 2 quarters · filed 2023-02-28 | $633.15M derived: sum of 3 quarters · filed 2023-02-28 | $992.58M 10-K · filed 2024-02-28 |
| 2021-09-30 | $227.87M 10-K · filed 2023-02-28 | $381.48M derived: sum of 2 quarters · filed 2023-02-28 | $740.91M 10-Q · filed 2022-11-07 | $1.04B derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $153.62M 10-K · filed 2023-02-28 | $513.04M 10-Q · filed 2022-08-04 | $808.02M derived: sum of 3 quarters · filed 2023-02-28 | $909.74M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $359.43M 10-K · filed 2023-02-28 | $654.41M derived: sum of 2 quarters · filed 2023-02-28 | $756.12M derived: sum of 3 quarters · filed 2023-02-28 | $773.39M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $294.98M 10-K · filed 2022-02-28 | $396.69M derived: sum of 2 quarters · filed 2022-02-28 | $413.96M derived: sum of 3 quarters · filed 2022-02-28 | $421.71M 10-K · filed 2023-02-28 |
| 2020-09-30 | $101.72M 10-K · filed 2022-02-28 | $118.98M derived: sum of 2 quarters · filed 2022-02-28 | $126.73M 10-Q · filed 2021-11-09 | $135.12M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $17.27M 10-K · filed 2022-02-28 | $25.02M 10-Q · filed 2021-08-10 | $33.41M derived: sum of 3 quarters · filed 2022-02-28 | $43.75M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $7.75M 10-K · filed 2022-02-28 | $16.14M derived: sum of 2 quarters · filed 2022-02-28 | $26.49M derived: sum of 3 quarters · filed 2022-02-28 | $34.91M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $8.39M 10-K · filed 2021-03-08 | $18.73M derived: sum of 2 quarters · filed 2021-03-08 | $27.16M derived: sum of 3 quarters · filed 2021-03-08 | $32.53M 10-K · filed 2022-02-28 |
| 2019-09-30 | $10.35M 10-K · filed 2021-03-08 | $18.77M derived: sum of 2 quarters · filed 2021-03-08 | $24.14M 10-Q · filed 2020-11-09 | $29.81M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-06-30 | $8.42M 10-K · filed 2021-03-08 | $13.79M 10-Q · filed 2020-08-05 | $19.47M derived: sum of 3 quarters · filed 2021-03-08 | $25.09M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-03-31 | $5.37M 10-K · filed 2021-03-08 | $11.04M derived: sum of 2 quarters · filed 2021-03-08 | $16.67M derived: sum of 3 quarters · filed 2021-03-08 | $22.07M derived: sum of 4 quarters · filed 2021-03-08 |
| 2018-12-31 | $5.67M 10-K · filed 2020-03-13 | $11.30M derived: sum of 2 quarters · filed 2020-03-13 | $16.70M derived: sum of 3 quarters · filed 2020-03-13 | $21.35M 10-K · filed 2020-03-13 |
| 2018-09-30 | $5.63M 10-K · filed 2020-03-13 | $11.03M derived: sum of 2 quarters · filed 2020-03-13 | $15.68M 10-Q · filed 2019-11-08 | $19.96M derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-06-30 | $5.40M 10-K · filed 2020-03-13 | $10.05M 10-Q · filed 2019-08-12 | $14.33M derived: sum of 3 quarters · filed 2020-03-13 | $18.84M derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-03-31 | $4.65M 10-K · filed 2020-03-13 | $8.93M derived: sum of 2 quarters · filed 2020-03-13 | $13.44M derived: sum of 3 quarters · filed 2020-03-13 | $18.08M derived: sum of 4 quarters · filed 2020-03-13 |
| 2017-12-31 | $4.28M 10-K · filed 2019-03-22 | $8.78M derived: sum of 2 quarters · filed 2019-03-22 | $13.42M derived: sum of 3 quarters · filed 2019-03-22 | $18.73M 10-K · filed 2019-03-22 |
| 2017-09-30 | $4.50M 10-K · filed 2019-03-22 | $9.14M derived: sum of 2 quarters · filed 2019-03-22 | $14.45M derived: sum of 3 quarters · filed 2019-03-22 | |
| 2017-06-30 | $4.64M 10-K · filed 2019-03-22 | $9.95M derived: sum of 2 quarters · filed 2019-03-22 | ||
| 2017-03-31 | $5.31M 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |